Navigation Links
Accuray Announces Results for Fourth Quarter and Fiscal Year 2013
Date:8/27/2013

of a discontinued variable interest entity

-(1,633)(3,505)(7,103)Impairment of indefinite lived intangible asset of discontinued variable interest entity

--(12,200)-Loss from deconsolidation of a variable interest entity

--(3,442)-Loss from discontinued operations, net of tax

-(1,633)(19,147)(7,103)Loss from discontinued operations attributable to non-controlling interest

-(1,382)(13,289)(6,411)Loss from discontinued operations attributable to stockholders

-(251)(5,858)(692)Net loss attributable to stockholders

$(18,715)$(20,264)$  (103,219)$ (72,042)Loss per share attributable to stockholdersBasic and diluted - continuing operations

$
(0.25)$
(0.28)$
(1.33)$
(1.01)Basic and diluted - discontinued operations

$
-$
(0.00)$
(0.08)$
(0.01)Basic and diluted - net loss

$
(0.25)$
(0.28)$
(1.41)$
(1.02)Weighted average common shares used in computing loss per shareBasic and diluted

74,27071,47373,28170,887Cost of revenue, selling and marketing, research and development, and general and administrative expenses include stock-based compensationcharges as follows:Cost of revenue 

$
455$
401$
,498$
,672Selling and marketing 

$
318$
84$
,121$
729Research and development 

$
494$
7$
,949$
2,340General and administrative 

$
830$
905$
3,648$
3,717 

  Accuray Incorporated  Consolidated Balance Sheets  (in thousands, except share amounts)  June 30,  June 30, 20132012 Assets  (unaudited)  (unaudited)  Current assets:  Cash, cash equivalents and investments 

$
74,397$
43,504 Restricted cash 

2,7281,560 Accounts receivable, net of allowance for doubtful accounts 

55,45867,890&#
'/>"/>

SOURCE Accuray Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Accuray to Host Investor Meeting at ASTRO 2013
2. Accuray to Report Financial Results for Fourth Quarter and Year End Fiscal 2013
3. Accuray is Honored for Delivering World-Class Customer Service
4. Accuray Incorporated to Present at 2013 Jefferies Global Healthcare Conference
5. Accuray Announces Results for Third Quarter Fiscal 2013
6. Accuray Incorporated to Report Financial Results for Third Quarter Fiscal 2013
7. Accuray Provides Clarification on Recently Initiated Voluntary Recalls
8. Dr. Emad Rizk Joins Accuray Board of Directors
9. Accuray Incorporated to Speak at Cowen and Company 33rd Annual Healthcare Conference
10. Accuray Prices Offering Of $100 Million Of 3.50% Convertible Senior Notes
11. Accuray Announces Results for Second Quarter Fiscal 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... Future Prospects for Companies in Antihistamines, Corticosteroids, ... - new study showing you trends, partnerships, and ... allergic rhinitis drugs heading? What are the commercial prospects ... you potential revenues and other trends to 2025, discussing ... report provides 273 tables, charts, and graphs. Discover the ...
(Date:9/4/2015)... , Sep. 04, 2015 ... of the "Investigation Report on China,s Sodium Ibandronate Market, ... and used in the clinic under the trade name of ... Austria in 1996, sodium ibandronate was approved by ... treatment of osteoporosis under the trade name of Boniva. However, ...
(Date:9/4/2015)... September 4, 2015 Hutchison ... that Hutchison MediPharma Limited ("HMP"), its drug R&D ... second proof-of-concept ("POC") trial of fruquintinib in patients ... in China .  The top-line ... meeting the primary efficacy endpoint of progression free ...
Breaking Medicine Technology:Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Investigation Report on China's Sodium Ibandronate Market 2010-2019 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3
... Late Stage Clinical Therapeutic Cancer... -- TUEBINGEN, Germany, September 21, 2010 ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... Inc., today announced that it reported positive preclinical ... Association for the Study of Diabetes (EASD).  CCX140, ... the chemokine receptor CCR2, improved metabolic function while ... in an animal model, and was well tolerated ...
Cached Medicine Technology:immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 2immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 3immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 4immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 5immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 6immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 7immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 8immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 9immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 10ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 2ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 3ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 4
(Date:9/4/2015)... ... , ... With TransCel from Pixel Film Studios users can simulate celluloid media ... TransCel users have full control over camera position and angle within 3D space from ... color, text, and more. With TransCel the possibilities are endless. , Users have full ...
(Date:9/4/2015)... GA (PRWEB) , ... September 04, 2015 , ... ... Bogart and the surrounding communities, is launching a charity effort to provide for ... Commonly referred to as an enlarged heart, restrictive cardiomyopathy often leads to diastolic ...
(Date:9/4/2015)... ... , ... Keeping mold top of mind is important when considering indoor air ... grow anywhere - on carpet, clothing, food, paper, and even in places you can’t ... the home is key to preventing mold growth, which if exposed to can lead ...
(Date:9/4/2015)... Pass, OR (PRWEB) , ... September 04, 2015 ... ... that markets a line of personal humidifying medical devices, announced its only mission ... climate, explains Bio-Logic Aqua® Research Founder Sharon Kleyne, body water evaporation is becoming ...
(Date:9/4/2015)... ... 04, 2015 , ... Lalonde Gordon ran a 44.64 seconds scorcher in the ... the men’s 400 meters final, with an impressive 44.89 seconds at the 2015 North ... Costa Rica in August 2015. The 44.64 time is a new NACAC Championship record. ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Releases TransCel, a New FCPX Transition 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 3Health News:September is Mold Awareness Month 2Health News:September is Mold Awareness Month 3Health News:September is Mold Awareness Month 4Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3
... PLACERVILLE, Calif., Dec. 31 Designed to help ... weight, PersonalDiets today,unveiled a new version of Plan-a-Meal ... Users can now easily customize ... high-tech gadgets. With a few keystrokes, dieters ...
... During a year-end,review with employees of The Quantum ... a solutions provider for the healthcare industry,President & ... growth of,Company revenues and expansion of business lines. ... offered his vision of Company developments in,the upcoming ...
... U.S. based Non-Governmental Organization (NGO), sent over $3,000,000 of vitally needed ... ... December 31, 2008 -- In a continent often defined by man-made ... the many uplifting success stories. Among the 53 countries ...
... Gram-negative spiral rods. Campylobacter jejuni ( C. ... milk and meat, especially chicken, is one of the ... mode of pathogenesis is not clear. , A research ... the World Journal of Gastroenterology addresses this ...
... -- China Medical Technologies,Inc. (the "Company") (Nasdaq: ... medical device,company that develops, manufactures and markets ... Company has completed the previously,announced sale of ... system,business (the "HIFU Business") to Chengxuan International ...
... SAN DIEGO, Dec. 30 Cardium Therapeutics,(NYSE Alternext ... its current,listing exchange indicating that the company is ... of the NYSE Alternext US LLC,(formerly the American ... on Form 10-Q, which was filed on November ...
Cached Medicine News:Health News:PersonalDiets Announces New Plan-A-Meal Tools to Help With New Year's Weight Loss Resolutions! 2Health News:The Quantum Group CEO Offers Year in Review 2Health News:The Quantum Group CEO Offers Year in Review 3Health News:The Quantum Group CEO Offers Year in Review 4Health News:Good News in Africa: Beyond the headlines 2Health News:China Medical Technologies Announces the Completion of the Sale of its HIFU Business 2Health News:China Medical Technologies Announces the Completion of the Sale of its HIFU Business 3Health News:China Medical Technologies Announces the Completion of the Sale of its HIFU Business 4Health News:China Medical Technologies Announces the Completion of the Sale of its HIFU Business 5Health News:Cardium Reports on Exchange Listing With NYSE Alternext US 2Health News:Cardium Reports on Exchange Listing With NYSE Alternext US 3Health News:Cardium Reports on Exchange Listing With NYSE Alternext US 4Health News:Cardium Reports on Exchange Listing With NYSE Alternext US 5
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: